title: Agomelatine: to be avoided, with or without a "patient booklet".
abstract: In early 2015, the European health authorities chose to keep agomelatine on the market despite its serious adverse effects (especially hepatic disorders), simply because patients would be provided with a treatment booklet. Yet this flimsy measure in no way improves patient care.
mesh_terms: D000081:Acetamides / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D006801:Humans; D010174:Pamphlets; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; C084711:agomelatine; D009281:Naphthalenes